Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test

August 28, 2012

Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails – such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.

A recent University of Colorado Cancer Center case study published in the describes the never-before-seen case of a patient who tested negative for EML4-ALK fusion based on the well-defined criteria for FISH assay as approved by FDA, but nevertheless experienced remission after treatment with crizotinib.

"The case implies that not all who might benefit from the drug are captured by the FDA-approved FISH assay. Perhaps despite the FDA pairing of crizotinib with FISH, other assays or other criteria for ALK/FISH positivity could be used," says paper co-author, Fred R. Hirsch, MD, PhD, investigator at the CU Cancer Center and professor of and pathology at the CU School of Medicine.

In fact, it was by chance that after the patient's negative FISH, Hirsch and colleagues chose to look deeper. Besides using FISH to stain sections of with the EML4-ALK fusion gene, the team used immunohistochemistry to look for the protein products of this fusion gene – not the faulty plans but the faulty results. Sure enough, in this case, the patient had the EML4-ALK fusion protein but apparently without the typical EML4-ALK fusion gene that should code for it.

The team looked deeper, using next-gen sequencing to discover what, exactly, was going on in the short arm of chromosome number 2, which harbors the EML4-ALK fusion gene. What they found looked less like a pair of clean breaks that reattached in the wrong places – say, like a snapped radius and ulna that found the wrong reattachments to make a rulna and an ulnius – but more like shattered fragments with genetic shards embedded in and around the primary sections.

"We think these genetic shards made the resulting gene look different enough from the typical EML4-ALK to avoid detection by the FDA approved FISH assay," Hirsch says.

Within two weeks of starting crizotinib, the patient reported improved pain symptoms and energy. Four months after starting the drug, a PET scan, which shows the sugar signatures of rapidly developing cancer cells, was negative. A chest CT scan showed the primary tumor had shrunk by 75 percent.

"Certainly FISH is a valuable assay to check for ALK-positive ," Hirsch says. "But we hope this work demonstrates the need to further refine this test, to ensure that all the patients who could benefit from crizotinib in fact receive the drug."

Together with CU Cancer Center colleagues including Drs. Doebele, Garcia, Aisner and Camidge, Hirsch is participating in a larger study comparing different assays for ALK testing to determine which assay or combination of assays identifies the most patients likely to benefit from crizotinib.

Explore further: First and only therapeutic drug for ALK-positive lung cancer approved

Related Stories

First and only therapeutic drug for ALK-positive lung cancer approved

August 31, 2011
In a major triumph for personalized medicine, the FDA approved the drug crizotinib for use with the lung cancer type known as ALK-positive.

ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium

July 5, 2011
ALK rearrangement has been found in 9.6% of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1%, reflecting how many patients might benefit from targeted therapies such ...

Study examines drug resistance in ALK positive lung cancer

January 19, 2012
Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell ...

Study: Inexpensive method detects ALK rearrangement in lung cancer patients

August 2, 2011
A relatively simple and inexpensive method may be used to determine whether a lung cancer patient is a candidate for crizotinib therapy, according to research published in the August issue of the Journal of Thoracic Oncology, ...

New research confirms need for lung cancer testing

February 2, 2012
Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.